As Questions Swirl Around Monkeypox Origins & Risk, Big Pharma Set Sights on Profits

As Questions Swirl Around Monkeypox Origins and Risk, Vaccine Makers Set Sights on Profits Politicians and public health officials are delivering mixed and confusing messages to the public about the origins of the monkeypox outbreak and the level of risk it poses to the public, while pharmaceutical companies are preparing to introduce monkeypox vaccines.

By: Michael Nevradakis, Ph.D. As an unprecedented outbreak of monkeypox spreads throughout the west, questions continue to swirl around the origin of the outbreak, the risk it poses to the public and the measures that may or may not be required to contain the virus.

Public health authorities in Belgium announced May 20 that a compulsory 21-day quarantine will be imposed for monkeypox patients, U.K. health authorities urged "High risk" contacts of monkeypox cases to self-isolate and to avoid children for 21 days, and Greece and other countries are considering similar measures.

In response to the monkeypox outbreak, the Biden administration placed a $119 million order for smallpox vaccines from Bavarian Nordic, the manufacturer of JYNNEOS, a smallpox vaccine also licensed to treat monkeypox.

The U.K. ordered more than 20,000 doses of JYNNEOS, while the European Centre for Disease Prevention and Control reportedly is set to recommend a monkeypox vaccine plan for EU member states.

"Jynneos will be available for those determined to be at high risk of either smallpox or monkeypox infection."This vaccine is also part of the Strategic National Stockpile, the nation's largest supply of potentially life-saving pharmaceuticals and medical supplies for use in a public health emergency that is severe enough to cause local supplies to be depleted.

The questions posited by Roberts point to the broader confusion, at least from what is evident through publicly available information, as to the origin of the monkeypox outbreak and how it is spreading.

https://www.thelibertybeacon.com/as-questions-swirl-around-monkeypox-origins-risk-big-pharma-set-sights-on-profits/